103
Participants
Start Date
September 20, 2006
Primary Completion Date
March 23, 2010
Study Completion Date
June 28, 2013
Omacetaxine mepesuccinate
"Induction:~1.25 mg/m\^2 subcutaneously, twice daily for 14 consecutive days every 28 days until response. Patients not demonstrating evidence of clinical response after 6 induction cycles will be considered for removal from the study.~Maintenance:~1.25 mg/m\^2 subcutaneously, twice daily for 7 consecutive days in a 28-day cycle, for up to 3 years."
Teva Investigational Site 050, Budapest
Teva Investigational Site 031, Berlin
Teva Investigational Site 002, The Bronx
Teva Investigational Site 005, Buffalo
Teva Investigational Site 010, Philadelphia
Teva Investigational Site 011, Baltimore
Teva Investigational Site 006, Atlanta
Teva Investigational Site 025, Toulouse
Teva Investigational Site 007, Jacksonville
Teva Investigational Site 029, Bordeaux
Teva Investigational Site 090, Bologna
Teva Investigational Site 008, Beech Grove
Teva Investigational Site 026, Vandœuvre-lès-Nancy
Teva Investigational Site 022, Lille
Teva Investigational Site 027, Strasbourg
Teva Investigational Site 030, Mannheim
Teva Investigational Site 020, Lyon
Teva Investigational Site 028, Paris
Teva Investigational Site 001, Houston
Teva Investigational Site 021, Le Chesnay
Teva Investigational Site 023, Poitiers
Teva Investigational Site 003, Los Angeles
Teva Investigational Site 080, Singapore
Teva Investigational Site 071, Hyderabad
Teva Investigational Site 004, Boston
Teva Investigational Site 013, Montreal
Teva Investigational Site 009, Toronto
Teva Investigational Site 024, Nice
Teva Investigational Site 070, Mumbai
Teva Investigational Site 060, Gdansk
Teva Investigational Site 061, Warsaw
Teva Investigational Site 040, London
Collaborators (2)
Cephalon
INDUSTRY
ChemGenex Pharmaceuticals
INDUSTRY
Teva Branded Pharmaceutical Products R&D, Inc.
INDUSTRY